Warburg effect, generates increased demand of glucose in cancer but is relatively underexplored phenomenon in existing commercial anti‐cancer drugs. Here, we present a Ru(II)‐bis‐bipyridyl‐morphocumin complex (2) encapsulated in a self‐assembling glucose‐functionalized co‐polymer P(G‐EMA‐co‐MMA) (where G = glucose; MMA = methyl methacrylate; EMA = ethyl methacrylate), designed to exploit Warburg effect and enhance cancer selectivity. The P(G‐EMA‐co‐MMA) polymer, synthesized via reversible‐addition fragmentation chain transfer (RAFT) polymerization, has a number average molecular weight (Mn, NMR) of 8000 g/mol. Complex 2, stable in aqueous media, selectively releases a cytotoxic, lysosome‐targeting compound morphocumin in the presence of excess H2O2, a reactive oxygen species (ROS) prevalent in tumor microenvironments. Complex 2 promotes ROS accumulation enhancing morphocumin release through a synergistic domino effect. Comparatively, 2 outperforms its curcumin Ru(II) complex (1) in solution stability, organelle specificity, and cellular mechanisms. Both 1 and 2 exhibit phototherapeutic effects under low‐intensity visible light, but their dark toxicity surpasses their photoactivity, highlighting they are superior as chemotherapeutic agents. Complex 2 induces apoptosis via mitochondrial pathway with 9‐fold increase in selectivity for pancreatic cancer cells (MIA PaCa‐2) over non‐cancerous HEK293 cells when delivered encapsulated in glucose‐conjugated polymer (DP@2)activity enhance further 5‐fold by glucose deprivation underscoring their potential in targeted cancer therapy.